Select the antibody for your application
Since E7 was identified as the primary oncogene in cervical cancer, the lack of robust functional monoclonal antibodies has proven to be a major obstacle in HPV research.
The difficulty in detecting E7 proteins in clinical samples was commonly attributed to the low abundance and high instability of E7 proteins. However, the development of the CERVIMAXTM product lines (IHC, WB, FC, IF) show that E7 is a robust and highly abundant antigen in clinical cervical cancer samples prepared under standardized protocols.
These products were developed by experts using a patented protocol proprietary to VALDOSPAN GmbH Vienna.
CERVIMAXTM is now available for purchasing world wide.